Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Carbendazim is a broad-spectrum systemic fungicide of the benzimidazole class. It is primarily used in agriculture to control fungal diseases in a wide variety of crops including cereals and fruits such as citrus and bananas[4][5]. Carbendazim acts by binding to β-tubulin in fungi and suppressing microtubule assembly dynamics[1][8], thereby inhibiting mitosis. In mammalian cells and cancer cell lines it also suppresses microtubule dynamic instability without significant depolymerization[6], leading to mitotic arrest. Although its exact binding site on tubulin differs from other benzimidazole compounds (not competing with colchicine or vinblastine), its antimitotic effect underlies both its antifungal activity and potential antineoplastic properties[1][6]. It has been investigated for use in lymphoma and solid tumors but is mainly known as an agricultural chemical rather than a pharmaceutical agent[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on carbendazim.